Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines

Taxol is a clinically active anticancer drug, which exerts its cytotoxicity by the unique mechanism of polymerizing tubulin monomers into microtubules and stabilizing microtubules. Our studies with ovarian (hamster CHO and human A2780) cells showed that taxol is a phase-specific agent that is much more cytotoxic to mitotic cells than interphase cells. First, the dose-survival pattern of taxol resembled that of other phase-specific agents, in which cell-kill reached a plateau at a certain concentration. This suggests that the asynchronous cell population consists of a taxol-sensitive (presumably mitotic) fraction and a taxol-resistant fraction. Second, the cells were more responsive to increased exposure time than to increased dose above the plateau concentration. Third, in both asynchrounous and synchronous cultures taxol was much more cytotoxic to mitotic than interphase (G1, S and G2) cells. Fourth, the taxol concentration needed to kill cells corresponded to the dose needed to block cells in mitosis. Although taxol blocked cells in mitosis, the mitotic block was of short duration. Cells escaped the mitotic block, without cytokinesis, and entered the next round of DNA synthesis to form multinucleated polyploid cells. Taxol was 15-to 25-fold more toxic to A2780 (human ovarian carcinoma) cells compared to CHO cells. This difference in sensitivity correlated with a higher intracellular taxol concentration in A2780 as compared to CHO as determined by either an ELISA assay or by [H3]-taxol uptake.

[1]  P. Schiff,et al.  Taxol stabilizes microtubules in mouse fibroblast cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Hortobagyi,et al.  Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.

[3]  Creasey Wa.  Modifications in biochemical pathways produced by the Vinca alkaloids. , 1968 .

[4]  Oka,et al.  Flow-systems analysis and characterization of protein contents and proliferating kinetics in ascites and solid tumors , 1976 .

[5]  R. Benjamin,et al.  A phase II trial of taxol in metastatic melanoma , 1990, Cancer.

[6]  M. Jordan,et al.  Mechanism of inhibition of cell proliferation by Vinca alkaloids. , 1991, Cancer research.

[7]  T. J. Fraser,et al.  Cell cycle phase specificity of antitumor agents. , 1972, Cancer research.

[8]  B. Bhuyan.  The action of streptozotocin on mammalian cells. , 1970, Cancer research.

[9]  E. G. Adams,et al.  Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects , 2004, Cancer Chemotherapy and Pharmacology.

[10]  J. Manfredi,et al.  Taxol binds to cellular microtubules , 1982, The Journal of cell biology.

[11]  D. Ettinger,et al.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .

[12]  R. Donehower,et al.  Development of polyploidization in taxol-resistant human leukemia cells in vitro. , 1990, Cancer research.

[13]  H. Madoc‐Jones,et al.  Interphase action of vinblastine and vincristine: Differences in their lethal action through the mitotic cycle of cultured mammalian cells , 1968, Journal of cellular physiology.

[14]  J. Sheppard,et al.  Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells. , 1980, Cancer research.

[15]  W. R. Bruce,et al.  Comparison of the Sensitivity of Normal Hematopoietic and Transplanted Lymphoma Colony-Forming Cells to Chemotherapeutic Agents Administered In Vivo , 1966 .

[16]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[17]  R. Donehower,et al.  Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. , 1988, Cancer research.

[18]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[19]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[20]  M. Citardi,et al.  Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine , 2005, Journal of Cancer Research and Clinical Oncology.

[21]  J. Koeller,et al.  A phase I trial of taxol given by a 6-hour intravenous infusion. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Tobey,et al.  Chapter 15 Mitotic Cells as a Source of Synchronized Cultures1 , 1969 .

[23]  R. Himes,et al.  Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. , 1985, Cancer research.

[24]  R. Schimke,et al.  Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Schiff,et al.  Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. , 1981, Biochemistry.

[26]  E. G. Adams,et al.  Cell cycle effects of CC-1065. , 1983, Cancer research.

[27]  D. V. Von Hoff,et al.  CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. , 1982, Cancer research.